@misc{oai:repo.qst.go.jp:00059781,
 author = {Zhang, Hong and Yoshikawa, Kyosan and Tamura, Katsumi and Tomemori, Takashi and Suhara, Tetsuya and Suzuki, Kazutoshi and Tanada, Shuji and Murata, Hajime and Sasaki, Yasuhito and Tsujii, Hirohiko and 張 宏 and 吉川 京燦 and 田村 克巳 and 留森 貴志 and 須原 哲也 and 鈴木 和年 and 棚田 修二 and 村田 啓 and 佐々木 康人 and 辻井 博彦},
 month = {Nov},
 note = {To evaluate whether positron emission tomography (PET) using 11C-methionine (MET) may early predict response to heavy-ion radiotherapy in patients with unresectable muscleskeletal malignant tumors. Thirty-five patients with 35 unresectable muscleskeletal malignant tumors were studied by MET PET at baseline and 11±4 days after completion of carbon radiotherapy. Clinical response ( reduction of tumor size by>50 parsent ) was evaluated after 6 months of therapy using standard imaging tecniques. The reduction of tumor MET uptale (mean±SD) after therapy was significantly different between responding (-49parsent ± 16parsent) and nonresponding tumors 
(-16parsent ± 13parsent). Optimal differentiation was achieved by a cutoff value of 30parsent
resuction of initial MET uptake. Applying this cutoff value as a criterion for a metaabolic response predicted clinical response with a sensitivity and specificity of 94.1parsent (16of 17 patients) and 94.4parsent (17or 18 patients),respectively. The results of survival rate predicted by MET PET were consistent well with the clinical results. MET PET imaging may differentiate responding and nonresponding tumors early in the carbon ion radiotherapy in patients with muscleskeletal malignant tumors., 第42回日本核医学会総会},
 title = {Initial Study of MET PET to Predict Response to Heavy-lon Radiotherapy in Patients with Muscleskeletal Malignant Tumors},
 year = {2002}
}